18th
18th Annual Meeting of the Japanese Society of Clinical
Neuropsychopharmacology joint with 38th Annual Meeting of Japanese Society of Newropsychopharmacology
October 1-3, 2008
SHINAGAWA PRINCE HOTEL Annex Tower Prince Hall, Tokyo, Japan
| FIRST AUTHOR INDEX | |||
|---|---|---|---|
| First Name | Last Name | No. | Title |
| Ishikawa | Kazuhiro | O1-A1 | The effect of oral urea for polydipsia-hyponatremia of the schizophrenic patients |
| Watabe | Kazushige | O1-A2 | Long-term prognosis in schizophrenic patients remedied by the hospital treatment of pharmacotherapy with olanzapine or risperidone in combination with psychoeducation under utilization of the Client-pathway. |
| Takeda | Toshihiko | O1-A6 | Clinical study of the medication for early psyuchosis. |
| Fukui | Naoki | O1-A10 | Predictors of hyperprolactinemia induced by antipsychotic agents |
| Ono | Shin | O1-A11 | Glucose tolerance test in patients with schizophrenia treated with antipsychotics |
| Yui | Kunio | O1-P11 | Serotonin antagonism and unsaturated fatty acid conposition in Asperger disorder |
| Morishita | Shigeru | O2-1 | Possible predictor of response to sertraline for major depression |
| Umene-Nakano | Wakako | O2-2 | The effects of sertraline on catecholaminergic system |
| Kato | Masaki | O2-3 | ABCB1 (MDR1) gene polymorphisms are associated with the clinicalresponse to paroxetine in patients with major depressive disorder |
| Hayashida | Maiko | O3-2 | The rat with hyperbilirubinemia may be a useful animal model for schizophrenia |
| Ohnuma | Tohru | P1-A1 | The relationship between the response of clinical symptoms and plasma olanzapine concentration based on pharmacogenetics-Juntendo University Schizophrenia Projects (JUSP)- |
| Hokyo | Akira | P1-A3 | Multifaced clinical studies about the cognitive function disorder of the schizophrenia using PPI |
| Nagata | Izumi | P1-A4 | A schizophrenia case of priapism caused by quetiapine |
| Takahashi | Hitoshi | P1-A7 | Efficacy and tolerability of aripiprazole in first-episode, drug naïve patients with schizophrenia: an open-label trial |
| Moriwaki | Masatsugu | P1-A8 | Treatment response of antipsychotics aripiprazole in a first episode psychotic disorder: measured by administering Positive and Negative Syndrome Scale (PANSS) and Brief Assessment of Cognition in Schizophrenia (BACS) |
| Uemura | Keiichi | P1-A13 | Three cases reports; Effect of Quetiapine augmentation for Aripiprazole-induced severe parkinsonism |
| Yamada | Kazuo | P1-B2 | Evidence-based guideline for treatment of acute bipolar depression and further problem |
| Kishi | Taro | P1-B6 | SNPs of CLOCK gene may predict the response of fluvoxamine treatment in Japanese major depressive disorder patients |
| Ago | Yukio | P1-C5 | Involvement of prefrontal dopaminergic system in antidepressant-like behavior by glucocorticoid receptor inhibition |
| Ezumi | Satoru | P1-C7 | The influence of dopamine D2 receptor on evaluation of the motivation using Run-way method in rats |
| Higuchi | Hiroshi | P1-E7 | Change in feeding by a siRNA plasmid for NPY Y1 receptor into hypothalamic paraventricular nucleus |
| Shuto | Makoto | P1-F1 | Mechanism underlying enhancement of trimethyltin-induced neuronal damage in adrenalectomized mice |
| Shirakawa | Takafumi | P1-F2 | Temporospaital patterns of COX-2 expression and pyramidal cell degeneration in the rat hippocampus after trimethyltin administration |
| Sugawara | Yuka | P1-G1 | Aripiprazole for the treatment of psychotic symptoms in patient with dementia with Lewy bodies. |
| Toru | Michio | P1-G5 | 5-HT1A receptor agonists in the treatment of mental disorder |
| Kida | Sayaka | P1-G8 | Four depressive patients in whom migraine was improved by paroxetine administration |
| Sakata | Shinichi | P2-A5 | Association analysis between the NMDA receptor subunit 2B gene and schizophrenia |
| Shinkai | Takahiro | P2-A6 | NMDA receptor subunit 2B (GRIN2B) gene and polydipsia in schizophrenia |
| Kishida | Ikuko | P2-A7 | Dysfunction of autonomic nervous system activity in schizophrenia and the influence of neuroleptics |
| Seok | Jeong Ho | P2-A9 | Prominent dysfunction of neural network associated with sustained attention in the patients with schizophrenia compared to the patients with major depression and the healthy controls |
| Ahn | Hee Won | P2-A10 | Heat Shock Protein 70-2 Gene Polymorphisms of Schizophrenia, Bipolar Disorder and Major Depressive Disorder |
| Yoon | Ji Young | P2-A11 | A Preliminary Study : Neural Correlates of Sad Feelings in Schizophrenia using Brain 99mTc-ECD |
| Kim | Jeong Lan | P2-A12 | Effects of Amisulpride Administration on Body Weight and Metabolic Parameters in Mice according to Sex |
| Ueoka | Yoshinori | P2-A13 | Relationship between cognitive function and clinical factors in people with schizophrenia |
| Takahashi | Hitoshi | P2-B3 | Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series |
| Jeong | Ryeong-Na | P2-B7 | Effect of milnacipran, an SNRI, in patients with major depression over 70 years old: a preliminary open label trial. |
| Song | Shin Ho | P2-B8 | The Characteristics of Depression in Cancer Patients on Chemotherapy |
| Ohno | Yukihiro | P2-C2 | Evaluation of seizure susceptibility in Scn1a (voltage-dependent sodium channel)-mutant rats: (1) Behavioral and EEG studies |
| Ishihara | Shizuka | P2-C3 | Evaluation of seizure susceptibility in Scn1a (voltage-dependent sodium channel)-mutant rats: (2) Neurochemical study on brain Fos expression |
| Shimizu | Saki | P2-C4 | Pharmacological analysis of the action of 5-HT1A agonists on extrapyramidal motor disorders: (1) Evaluation using the mouse pole-test |
| Imaki | Junta | P2-C5 | Pharmacological analysis of the action of 5-HT1A agonists on extrapyramidal motor disorders: (2) Effects on haloperidol-induced forebrain Fos expression |
| Watanabe | Akiko | P2-C11 | Identification of a causative gene for prepulse inhibition by QTL analysis |
| Takamatsu | Yukio | P2-D1 | Inhibitory role of inducible cAMP early repressor (ICER) in methamphetamine-induced locomotor sensitization: a study in ICER knockout and ICER I overexpressing mice |
| Ito | Koki | P2-E2 | Valproate blocks a high dose of methamphetamine-induced apoptosis in the medial prefrontal cortex and accompanied neuroplastic PPI deficit |
| Takeshima | Mika | P2-E4 | Effect of baicalein, a flavonoid, against methamphetamine-induced neurotoxicity |
| Shuto | Takahide | P2-E5 | Reversal of methamphetamine sensitization by repeated dopamine D1 receptor agonism: Effect on the affinity of dopamine D1 and D2 receptor |
| Someya | Megumi | P2-E6 | Effect of theanine on cultured monoaminergic neuronal and glial cells |
| Kitanaka | Junichi | P2-E9 | Association of brain histaminergic neurotransmission with alteration of the expression pattern of methamphetamine-induced stereotyped behavior |
| Tadori | Yoshihiro | P2-F1 | Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors |
| Kato | Takahiro | P2-F2 | Aripiprazole Inhibits Interferon-gamma-Induced Microglial Activation via Intracellular Ca²+ Regulation in Vitro |
| Umezu | Toyoshi | P2-F3 | Behavioral Pharmacology of plant-derived substances (19): Interactions between constituents of plant-derived essential oils and psychoactive drugs on the ambulatory activity in mice |
| Yun | Jeong Ju | P2-G5 | No association of the -521C/T polymorphism in the promoter region of DRD4 gene with ADHD |
| Nishizawa | Daisuke | P2-G7 | Association of GIRK3 gene polymorphismswith methamphetamine and alcohol dependence |
| Kim | Tae Yong | P2-G8 | Cognitive deficits associated with posttraumatic stress disorder |
| Jeong | Jong-Il | P2-G9 | The Charactristics of the Dropout Patients from an Alcoholism Treatment Program |
| Jeong | Jong Hyun | P2-G10s | Open-label Trial of Aripiprazole in Tourette’s Disorder patients |
| Tomotake | Masahito | P3-A2 | Quality of life and cognitive function in outpatients with schizophrenia |
| Watanabe | Junzo | P3-A3 | Dose dependent effect of risperidone on QT interval obtained by 24-hour Holter ECG recordings |
| Ono | Hisae | P3-A4 | A double blind dose response study comparing rapid acting intramuscular olanzapine and placebo in agitated schizophrenia -Results from the All Patients- |
| Ono | Hisae | P3-A5 | A double blind dos response study comparing rapid acting intramuscular olanzapine and placebo in agitated schizophrenia – Results from a subgroup: patients with a PANSS-EC score of at least 20- |
| Ono | Hisae | P3-A6 | A double blind dose response study comparing rapid acting intramuscular olanzapine and placebo in agitated schizophrenia -Results from a subgroup: patients with baseline ACES scores of 1 or 2- |
| Shioda | Katsutoshi | P3-A8 | Risperidone and low ambient temperature potently reverse MDMA( 3,4-Methylenedioxymethamphetamine)-induced hyperthermia in rats |
| Kuramochi | Motoki | P3-A9 | Actual use of olanzapine orally disintegrating tablets (ODT) in acute schizophrenic patients: From an analysis of a post-marketing surveillance. |
| Kanekawa | Hideo | P3-A11 | Switching treatment to Zyprexa Zydis for dysphagia in elderly schizophrenic patients |
| Nishiuma | Shinichi | P3-B1 | Association Between Early and Rapid Weight Gain and Change in Weight Over One Year of Olanzapine Therapy in Patients with Schizophrenia |
| Fukunaka | Yuko | P3-B4 | Association study between the NPR-1 gene polymorphism (M341I) and polydipsia in schizophrenia |
| Tsuneyama | Nobuto | P3-B10 | QT change after replacement of antipsychotic agents: a case report |
| Yoshimura | Reiji | P3-C2 | Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline |
| Obara | Yoshihiko | P3-C4 | A case of bipolar disorder that became manic state after depressed state was improved by administration of cilostazol |
| Murata | Yusuke | P3-C9 | Multivariate analysis of risk factors for the occurrence of paroxetine discontinuation syndrome |
| Yamakawa | Yuriko | P3-D3 | A survey to examine patterns of prescribing atypical antipschichotic drugs for outpatients with schizophrenia |
| Seo | Tomonori | P3-E5 | T-817MA, a novel neurotrophic compound, ameliorates phencyclidine-induced disruption of sensorimotor gating |
| Matsuda | Tomomi | P3-E7 | Effects of Drugs on Freezing Behavior and Panic-like Behavior of Olfactory Bulbectomized Rats in the Fear-conditioning Device |
| Nomura | Hiroshi | P3-E8 | Representation of fear memory in lateral amygdala |
| Kakui | Nobukazu | P3-E10 | Anxiolytic profile of mirtazapine in rat conditioned fear stress model: functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptor. |
| Utsunomiya | Kensuke | P3-F1 | No association between the leptin receptor gene (LEPR ) polymorphism (Gln223Arg) and late-onset Alzheimer,s disease |
| Kishi | Taro | P3-F2 | Association analysis of Rev-erb alpha gene (NR1D1) with the fluvoxamine therapeutic response in major depressive disorder in the Japanese population |
| Lakshmi N. | Yatham | SL1 | Advances in Management of Bipolar Disorder |
| Ronald S. | Duman | SL2 | Abraham Ribcoff Research Facilities, Laboratory Molecular Psychia, Yale University School of Medicine |
| Ishigoooka | Jun | PL1 | Dialogue between Basic Researchers and Clinical Practitioners in a Global Age -Linking Clinical Intelligence to New Drug Development- |
| Yamawaki | Shigeto | PL2 | Dialogue between Basic Researchers and Clinical Practitioners in a Global Age Japan’s Leadership in the Next Step of Neuropsychopharmacology in a Global World |
| Hayashi | Teruo | S2-3 | Sigma-1 receptor: the potential target for a new class of antidepressants |
| Konno | Michiko | S3-2 | Melatonin agonists: a novel option in the treatment of sleep disorders |
| Kanbayashi | Takeshi | S3-3 | Recent Advance of Treatments for Narcolepsy and Hypersomnia |
| Takano | Akihiro | S4-2 | Clinical evaluation of CNS drugs with PET |
| Ishiwata | Kiichi | S4-4 | Strategy for development of imaging biomarkers |
| Narita | Minoru | S6-1 | Differences in neuronal toxicity and its molecular mechanisms between methamphetamine and methylphenidate |
| Uchiyama | Makoto | S6-4 | Clinical advantages and disadvantages of methylphenidate in the treatment of hypersomnia |
| Fukuda | Masato | S7-1 | Near-infrared spectroscopy (NIRS) for diagnosis and treatment of schizophrenia |
| Watanabe | Hiroyuki | S7-2 | Strategies for improving medical adherence in patients with schizophrenia |
| Inokuchi | Kaoru | S9-1 | Molecular mechanisms underlying fear memory formation |
| Yamamoto | Shigeto | S9-3 | A novel therapeutic approach for the treatment of post-traumatic stress disorder (PTSD): enhancing the impaired extinction of fear memory. |
| Dieter | Naber | CL-2 | Methodological aspects of the SWN |
| Matsumura | Hitoshi | CL-3 | Impact of SWNS-J on Japanese clinical psychiatry |
| Yamauchi | Toshio | ES1-1 | Overview of new antiepileptic drugs -gabapentin, topiramate and lamotrigine- |
| Oguni | Hirokazu | ES1-2 | Pharmacological treatment of childhood epilepsy |
| Inoue | Yushi | ES1-3 | Medical treatment of epilepsy in adults |
| Dieter | Naber | LS1 | Subjective well-being under neuroleptic treatment. Relationships to psychopathology, compliance and remission |
| Ronald S. | Duman | LS3 | Cellular Mechanisms of Antidepressant Actions |
| John W. | Newcomer | LS5 | General medical health challenges associated with psychotic disorders |
| Lakshmi N. | Yatham | LS7 | Neurobiology of Bipolar Disorder |
| Joseph | Peuskens | EV1 | Optimization of Long Term Treatment Outcome in Schizophrenia |
| Jonathan R.L. | Schwartz | EV2 | Modafinil in the Treatment of Excessive Sleepiness: 15 Years of Research and Clinical Experience |
| Frederick W. | Reimherr | EV7 | Neurobiology of Bipolar Disorder |